Caris Life Sciences (CAI) Short term Debt (2024 - 2026)

Caris Life Sciences' Short term Debt history runs 3 years deep, the most recent figure standing at $173000.0 for Q1 2026.

• In Q1 2026, Short term Debt changed N/A year-over-year to $173000.0; the TTM figure through Mar 2026 stood at $173000.0 (changed N/A YoY), while the FY2025 annual figure was $169000.0, down 99.72% from the prior year.
• Short term Debt was $173000.0 for Q1 2026 at Caris Life Sciences, up from $169000.0 in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $60.1 million in Q4 2024 to a low of $95000.0 in Q2 2025.
• Historically, Short term Debt has averaged $12.1 million across 3 years, with a median of $169000.0 in 2025.
• Biggest YoY gain for Short term Debt was 99.72% in 2025; the steepest drop was 99.72% in 2025.
• A 3-year view of Short term Debt shows it stood at $60.1 million in 2024, then sank by 99.72% to $169000.0 in 2025, then rose by 2.37% to $173000.0 in 2026.
• The last three Short term Debt figures came in at $173000.0 (Q1 2026), $169000.0 (Q4 2025), and $164000.0 (Q3 2025), per Business Quant data.